Provenge Scores In Phase III; Will Dendreon Need To Confirm The IMPACT?

Dendreon's release of positive Phase III results for immunotherapeutic Provenge - including a four-month overall survival benefit compared to placebo - begs the question of whether FDA will now approve the prostate cancer vaccine without a confirmatory trial